NCT05743933 Chongqing Adrenogenic Autonomic Cortisol Secretion Cohort Study
| NCT ID | NCT05743933 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chongqing Medical University |
| Condition | Diagnosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-02-17 |
| Primary Completion | 2033-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-02-17 with a primary completion date of 2033-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.
Eligibility Criteria
Inclusion Criteria: * CT examination revealed adrenal nodules (maximum diameter ≥10mm); * Serum cortisol \> 50nmol/L after 1mg dexamethasone inhibition test (1mg-DST). Exclusion Criteria: * Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma/paraganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function. * Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy. * Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis. * Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.
Contact & Investigator
Qifu Li, PhD
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT05743933 clinical trial?
This trial is open to participants of all sexes, studying Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05743933 currently recruiting?
Yes, NCT05743933 is actively recruiting participants. Contact the research team at liqifu@yeah.net for enrollment information.
Where is the NCT05743933 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT05743933 clinical trial?
NCT05743933 is sponsored by Chongqing Medical University. The principal investigator is Qifu Li, PhD at First Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 200 participants.